Roundup Campaign Details

Prices listed are the current retail value and may be higher or lower based on availability, size of budget, demand, volatility and additional filters.

  • Roundup lead
    Call for pricing
  • Roundup signed
    Call for pricing

Roundup Criteria

  • Direct exposure to Roundup from work or home use for 5 years or longer
  • Diagnosed with any of the following cancers :
    • Adult T-cell lymphoma/leukemia (T-ATLL)
    • Aggressive NK-cell leukemia (NK-AL)
    • Anaplastic large T/null-cell lymphoma (T/N-ALCL)
    • Blastic mantle cell lymphoma (B- BMCL)
    • Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
    • B-lymphoblastic leukemia (BP-ALL)
    • B-lymphoblastic lymphoma (BP-LBL)
    • B-prolymphocytic leukemia (B-PLL)
    • Burkitt lymphoma (B-BL)
    • Chronic lymphocytic leukemia (B-CLL)
    • Composite lymphoma (CL: % %)
    • Cutaneous CD4-positive small/medium T-cell lymphoma (T-CCD4SML)
    • Cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (T-CCD8ECL)
    • Dendritic/histiocytic neoplasm (DHN)
    • Diffuse follicular lymphoma (B-DFL)
    • Diffuse large B-cell lymphoma (B-DLCL)
    • Diffuse lymphocyte-predominant (HD-LP-D)
    • Diffuse mantle cell lymphoma (B-DMCL)
    • EBV-driven lymphoproliferative disorder (EBVLD)
    • Enteropathy-type T-cell lymphoma (T-EATL)
    • Extranodal marginal zone B-cell Lymphoma (B-EMZL)
    • Follicular lymphoma (B-FL)
    • Hairy cell leukemia (B-HCL)
    • Hepatosplenic T-cell lymphoma (T-HSGDL)
    • Interfollicular (HD-IF)
    • Langherns cell histiocytosis (LCH)
    • Lymphocyte-depleted (HD-LD)
    • Lymphocyte-rich (HD-LR)
    • Lymphoplasmacytic lymphoma (B-LPL)
    • Malignant lymphoma unclassifiable (ML-UC)
    • Mantle cell lymphoma (B-MCL-IS)
    • Mast cell disease (MCD)
    • Mixed cellularity (HD-MC)
    • Mycosis fungoides (T-MF)
    • Nasal NK-T-cell lymphoma (NK/T)
    • NK-cell granular lymphocytic proliferation (NK-GLP)
    • Nodal marginal zone B-cell lymphoma (B-NMZL)
    • Nodular lymphocyte-predominant (HD-LP-N)
    • Nodular mantle cell lymphoma (B-NMCL)
    • Nodular sclerosis (HD-NS)
    • Non-hodgin lymphoma (NHL)
    • Not otherwise specified (HD-NOS)
    • Peripheral gamma-delta T-cell lymphoma (T-PGDL)
    • Peripheral T-cell lymphoma (T-PTCL)
    • Plasma cell dyscrasia (B-PCD)
    • Plasma cell myeloma (B-PCM)
    • Plasmacytoma (B-PC)
    • Post-transplantation lymphoproliferative disorder (PTLD)
    • Primary cutaneous CD30-positive lymphoproliferative disorder (T-PCLPD-CD30)
    • Sezary syndrome (T-SS)
    • Small lymphocytic lymphoma (B-SLL)
    • Splenic diffuse red pulp small B-cell lymphoma (B-SDRPL)
    • Splenic marginal zone B-cell lymphoma (B-SMZL)
    • Subcutaneous panniculitis-like T-cell lymphoma (T-SPTL)
    • T-cell granular lymphocytic proliferation (T-GLP)
    • T-cell lymphoproliferative disorder of childhood, Epstein-Barr virus positive (TLPDC-EBV)
    • T-lymphoblastic leukemia (TP-ALL)
    • T-lymphoblastic lymphoma (TP-LBL)
    • T-prolyrnphocytic leukemia (T-PLL)
    • Unclassifieable B-cell lymphoma (B-UCL)
  • No previous diagnosis
  • No legal representation


We welcome you to contact Mass Torts USA for more information
about our products and services.